The following represents disclosure information provided by authors of this abstract. The ASCO Scientific Program Committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered self-held and compensated unless otherwise noted. Employment/Leadership relationships are considered compensated employment unless otherwise noted. L = Leadership, U = Uncompensated, I = Immediate Family Member, B = Both Myself and Immediate Family Member, Inst = My Institution
Five years' results of the German ARO 04-01 trial of concurrent 72 Gy hyperfractionated accelerated radiation therapy (HART) plus once weekly cisplatinum/5-FU versus mitomycin C/5-FU in stage IV head and neck cancer.
Volker Budach
No relevant relationships to disclose
Chie-Hee Cho
No relevant relationships to disclose
Benedikt Sedlmaier
No relevant relationships to disclose
Michael Wittlinger
No relevant relationships to disclose
Heinrich Iro
No relevant relationships to disclose
Rita Engenhart-Cabillic
No relevant relationships to disclose
Matthias Hautmann
No relevant relationships to disclose
Juergen Strutz
No relevant relationships to disclose
Michael Flentje
No relevant relationships to disclose
Beatrix Hueltenschmidt
No relevant relationships to disclose
Lutz Moser
No relevant relationships to disclose
Martin Bleif
No relevant relationships to disclose
Wilfried Budach
No relevant relationships to disclose
Susanne Staar
No relevant relationships to disclose
Gerd Becker
No relevant relationships to disclose
Silke Tribius
No relevant relationships to disclose
Petra C. Feyer
No relevant relationships to disclose
Klaus Dieter Wernecke
No relevant relationships to disclose
Jochen Werner
No relevant relationships to disclose